Healthcare entity
All 2 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 2 also mention Dinesh Patel, the most common co-covered peer. That works out to roughly 0.2 stories per week across a 90-day span. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window.
Last mentioned: Jun 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 2 also mention Dinesh Patel, the most common co-covered peer. That works out to roughly 0.2 stories per week across a 90-day span. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.1. Protagonist Therapeutics appears in 2 tracked Healthcare stories published from March 17, 2026 through June 14, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 236 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Protagonist Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated top-line data from the Phase 3 VERIFY clinical trial.
Q4 Earnings
Scheduled announcement of quarterly financial results and pipeline update.
VERIFY Enrollment
Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
J&J Milestone
Protagonist receives $231M milestone payment for icotrokinra progress.
Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk.
Source: Equity Eagle · Equity Eagle
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Source: themarketsdaily.com · tickerreport.com
Protagonist Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
